---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-029156"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2023-08-16T23:59:59+00:00"
generated_at: "2026-06-11T08:18:31.177588+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma Q2 net loss $4.2M; cash $32.4M; advances antiviral pipeline

## Summary
- Net loss $4.2M ($0.41/share) vs $24.4M ($3.00) in Q2 2022, which included $19.1M goodwill impairment and legal settlement.
- Cash $32.4M at June 30, 2023 vs $37.1M at Dec 31, 2022; management expects sufficient for 12 months.
- On track to initiate Phase 2a trial for CC-42344 (influenza A) in H2 2023 pending UK MHRA clearance.
- Selected novel protease inhibitor CDI-988 as lead oral norovirus candidate; Phase 1 cleared by Australian regulator.
- Completed $4.0M private placement of common stock with directors Fred Hassan and Phillip Frost.

## SEC filing metadata
- accession: 0001493152-23-029156
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2023-08-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315223029156/0001493152-23-029156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315223029156/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-029156
- JSON: https://secwatch.observer/filing/0001493152-23-029156.json
- Plain text: https://secwatch.observer/filing/0001493152-23-029156.txt

## Key facts
- Earnings Releases
  Cocrystal Pharma, Inc. reported financial results for the three and six months ended June 30, 2023.
  - Period: the three and six months ended June 30, 2023
  - Result: reported results
  source text: Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three and six months ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315223029156/0001493152-23-029156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.